浙江恒研医药

Zhejiang Hengyan Pharmaceutical is a China-based biotechnology company dedicated to the discovery and development of next-generation small molecule therapeutics. Founded in 2020 and headquartered in Hangzhou, the company focuses on addressing unmet medical needs in oncology, particularly targeting drug-resistant mutations in solid tumors. Its lead candidate, HY-001, is a potent fourth-generation EGFR inhibitor designed to treat non-small cell lung cancer patients who have developed the C797S resistance mutation. The company's R&D strategy emphasizes precision medicine and the development of best-in-class therapies through an efficient internal research platform. Hengyan Pharma is led by a team of industry veterans with extensive experience in global drug discovery and clinical development.